For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. (HealthDay News) — For patients with ischemic stroke, sodium-glucose ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community needs to figure out how to keep patients on the drugs long term to fully ...

Increased adoption of GLP-1 drugs, rising catastrophic claims and other cost pressures are driving employer-sponsored health insurance costs to new heights. Current projections range from 7% to 8% ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions ...

Today, we talk a whole lot about RFK Jr., and also President-elect Donald Trump. Plus, we note that GLP-1 drugs can increase a person’s risk of aspiration when undergoing surgery. Have a nice week!

The first GLP-1 medication was prescribed beginning in 2006, and the authors included cases beginning in 2000 to increase the power of the study, they noted. Note: The study featured in this news ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...